日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

β-catenin attenuation leads to up-regulation of activating NKG2D ligands and tumor regression in BrafV600E-driven thyroid cancer cells

β-catenin 衰减导致 BrafV600E 驱动的甲状腺癌细胞中 NKG2D 配体活性上调和肿瘤消退

Minjing Zou, Suhad Al-Yahya, Monther Al-Alwan, Huda A BinEssa, Khalid S A Khabar, Falah Almohanna, Abdullah M Assiri, Abdulmohsen Altaweel, Amal Qattan, Brian F Meyer, Ali S Alzahrani, Yufei Shi

Mutation spectrum of EXT1 and EXT2 in the Saudi patients with hereditary multiple exostoses

沙特阿拉伯遗传性多发性外生骨疣患者EXT1和EXT2基因的突变谱

Al-Zayed, Zayed; Al-Rijjal, Roua A; Al-Ghofaili, Lamya; BinEssa, Huda A; Pant, Rajeev; Alrabiah, Anwar; Al-Hussainan, Thamer; Zou, Minjing; Meyer, Brian F; Shi, Yufei

Cyp24a1 Attenuation Limits Progression of BrafV600E -Induced Papillary Thyroid Cancer Cells and Sensitizes Them to BRAFV600E Inhibitor PLX4720

CYP24A1 衰减限制了 BrafV600E 诱导的乳头状甲状腺癌细胞的进展,并使其对 BRAFV600E 抑制剂 PLX4720 敏感

Minjing Zou, Essa Y Baitei, Huda A BinEssa, Futwan A Al-Mohanna, Ranjit S Parhar, René St-Arnaud, Shioko Kimura, Catrin Pritchard, Ali S Alzahrani, Abdullah M Assiri, Brian F Meyer, Yufei Shi

TSH overcomes Braf(V600E)-induced senescence to promote tumor progression via downregulation of p53 expression in papillary thyroid cancer

TSH 通过下调甲状腺乳头状癌中的 p53 表达克服 Braf(V600E) 诱导的衰老,促进肿瘤进展

M Zou, E Y Baitei, R A Al-Rijjal, R S Parhar, F A Al-Mohanna, S Kimura, C Pritchard, H A Binessa, A S Alzahrani, H H Al-Khalaf, A Hawwari, M Akhtar, A M Assiri, B F Meyer, Y Shi

KRAS(G12D)-mediated oncogenic transformation of thyroid follicular cells requires long-term TSH stimulation and is regulated by SPRY1

KRAS(G12D)介导的甲状腺滤泡细胞癌变需要长期TSH刺激,并受SPRY1调控。

Zou, Minjing; Baitei, Essa Y; Al-Rijjal, Roua A; Parhar, Ranjit S; Al-Mohanna, Futwan A; Kimura, Shioko; Pritchard, Catrin; BinEssa, Huda; Alanazi, Azizah A; Alzahrani, Ali S; Akhtar, Mohammed; Assiri, Abdullah M; Meyer, Brian F; Shi, Yufei